glp-1 latest use tripled among non-diabetics, reaching $5.8B in 2022 GLP1 medicines now address weight
Description
It helps maintain muscle mass, keeps hunger in check, and even enhances the release of hormones that promote a feeling of fullness
Drugs that are on the market only have limited effects
The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)
Have recently been diagnosed with a sexually transmitted disease (STD)
